SCHEMBL1924879

SCHEMBL1924879

CCOC(=O)[C@H]1CC[C@@H](Nc2ccc(F)cc2N)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 2/20 0.55
ALDH1A1 P00352 3/20 0.48
TDP1 Q9NUW8 1/20 0.48
LGMN Q99538 2/20 0.44
PTGER4 P35408 1/20 0.42
KCNQ2 O43526 2/20 0.42
KCNQ3 O43525 1/20 0.42
KCNQ4 P56696 1/20 0.42
KCNQ5 Q9NR82 1/20 0.42
PKM P14618 1/20 0.41
ATM Q13315 1/20 0.41
HSD11B1 P28845 1/20 0.41
TP53 P04637 1/20 0.40
POLB P06746 1/20 0.40
MAPT P10636 1/20 0.40
RECQL P46063 1/20 0.40
CHEK1 O14757 1/20 0.40
NTRK1 P04629 1/20 0.40
MET P08581 1/20 0.40
PIM1 P11309 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1924881 1.00 ALOX15 (0.55) ALOX15ALDH1A1TDP1LGMNPTGER4
SCHEMBL13594578 0.89 ALDH1A1 (0.51) ALOX15ALDH1A1TDP1PKMATM
SCHEMBL2143238 0.86 ALDH1A1 (0.48) ALOX15ALDH1A1TDP1PKMATM
SCHEMBL1834076 0.83 KDM4E (0.50) ALOX15ALDH1A1TDP1LGMNPKM
SCHEMBL4714159 0.82 ALDH1A1 (0.57) ALOX15ALDH1A1POLBMAPTSMN1; SMN2
SCHEMBL1925316 0.82 HCAR3 (0.52) ALDH1A1TDP1TP53POLBMAPT
SCHEMBL1925313 0.82 HCAR3 (0.52) ALDH1A1TDP1TP53POLBMAPT
SCHEMBL20985361 0.81 HDAC1 (0.47) ALOX15POLBCHEK1NTRK1MET
SCHEMBL20985359 0.81 HDAC1 (0.47) ALOX15POLBCHEK1NTRK1MET
SCHEMBL3322292 0.80 ALDH1A1 (0.50) ALDH1A1TDP1PKMATMTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12036209-B2 Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides ARVINAS OPERATIONS, INC. (US) 2024-07-16 US disclosed
EP-1434579-B1 IMIDAZOLE DERIVATIVES AS ANTIINFLAMMATORY AGENTS AMGEN INC (US) 2011-06-08 EP disclosed
US-20100048565-A1 BENZIMIDAZOLE DERIVATIVES FRENKEL ALEXANDER DAVID 2010-02-25 US disclosed
US-7635774-B2 2-Amino-imidazole derivatives; modulate the expression and/or function of proteins involved in inflammation, immune response regulation and cell proliferation AMGEN INC. (US) 2009-12-22 US disclosed
US-20070037803-A1 2-Amino-imidazole derivatives; modulate the expression and/or function of proteins involved in inflammation, immune response regulation and cell proliferation AMGEN SF, LLC (US) 2007-02-15 US disclosed
US-7132438-B2 Benzimidazole derivatives AMGEN INC. (US) 2006-11-07 US disclosed
US-20030144286-A1 Benzimidazole derivatives TULARIK, INC 2003-07-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070037803-A1 2-Amino-imidazole derivatives; modulate the expression and/or function of proteins involved in inflammation, immune response regulation and cell proliferation IDO2, IRF2BP2, IRF3 ALOX15 2169/4885ALDH1A1 3628/4885TDP1 3236/4885
US-12036209-B2 Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides IRAK1, IRAK4, IRAK2 ALOX15 4514/4885ALDH1A1 2211/4885TDP1 985/4885
US-20030144286-A1 Benzimidazole derivatives NFATC1, STAT1, IRF3 ALOX15 1735/4885ALDH1A1 1869/4885TDP1 3564/4885
US-20100048565-A1 BENZIMIDAZOLE DERIVATIVES NFATC1, STAT1, IRF3 ALOX15 1735/4885ALDH1A1 1869/4885TDP1 3564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.